NCT03118570 - A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

November 12, 2020

Conditions

Osteogenesis Imperfecta, Type IOsteogenesis Imperfecta Type IIIOsteogenesis Imperfecta Type IV

Interventions

DRUG

setrusumab

Intravenous infusion

DIETARY_SUPPLEMENT

Calcium

tablets

DIETARY_SUPPLEMENT

Vitamin D

capsules

DRUG

zoledronic acid (optional)

Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.

Trial Locations (25)

15225

Mereo Investigator Site, Pittsburgh

21287

Mereo Investigator Site, Baltimore

32207

Mereo Investigator Site, Jacksonville

35294

Mereo Investigator Site, Birmingham

37232

Mereo Investigator Site, Nashville

45229

Mereo Investigator Site, Cincinnati

55101

Mereo Investigator Site, Saint Paul

63110

Mereo Investigator Site, St Louis

77030

Mereo Investigator Site, Houston

87106

Mereo Investigator Site, Albuquerque

97239

Mereo Investigator Site, Portland

012115

Mereo Investigator Site, Boston

Unknown

Mereo Investigator Site, Toronto

Mereo Investigator Site, Montreal

Mereo Investigator Site, Québec

Mereo Investigator Site, Aarhus

Mereo Investigator Site, Odense

Mereo Investigator Site, Paris

Mereo Investigator Site, Lyon

Mereo Investigator Site, Paris

Mereo Investigator Site, Cambridge

Mereo Investigator Site, Newcastle upon Tyne

Mereo Investigator Site, Oxford

Mereo Investigator Site, Bristol

Mereo Investigator Site, London